Evidence map›Paper›PMID 30768776›Full record

ArticleJournal of the International AIDS Society2019

Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study.

Darrell P Wheeler, Sheldon D Fields, Geetha Beauchamp, Ying Q Chen, Lynda M Emel, Lisa Hightow-Weidman, Christopher Hucks-Ortiz, Irene Kuo, Jonathan Lucas, Manya Magnus and 8 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06162897 (Implementation of a Triadic Network Case Management Intervention for Along the Status Neutral HIV Care Continuum), which is not on this map. Cited by 76 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 7 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06162897 narecruitingnot on this mapstarted 2022, after this paper: background citation

Implementation of a Triadic Network Case Management Intervention for Along the Status Neutral HIV Care Continuum

TypeinterventionalSponsorUniversity of ChicagoRan2022 to 2027Enrolled180ConditionsHIV, Pre-exposure Prophylaxis, Case ManagementArmsDyadic Case Management
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 7 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men: A Systematic Review and Meta-analysis.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pre-Exposure Prophylaxis Interventions among Black Sexual Minority Men: A Systematic Literature Review.International journal of environmental research and public health · 2022
    Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 3 countries.

Darrell P WheelerSchool of Social Welfare, University at Albany - SUNY, Albany, NY, USA.ORCID 0000-0002-9200-920X
Sheldon D FieldsSchool of Health Professions, New York Institute of Technology, New York, NY, USA.
Geetha BeauchampStatistical Center for HIV/AIDS Research & Prevention (SCHARP), Vaccine and Infectious Disease Division (VIDD), Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ying Q ChenStatistical Center for HIV/AIDS Research & Prevention (SCHARP), Vaccine and Infectious Disease Division (VIDD) and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Lynda M EmelStatistical Center for HIV/AIDS Research & Prevention (SCHARP), Vaccine and Infectious Disease Division (VIDD), Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Lisa Hightow-WeidmanDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Christopher Hucks-OrtizJohn Wesley Community Health Institute, Inc., Commerce, CA, USA.
Irene KuoDepartment of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Jonathan LucasScience Facilitation Department, FHI 360, Durham, NC, USA.
Manya MagnusDepartment of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Kenneth H MayerThe Fenway Institute, Fenway Health, Boston, MA, USA.ORCID 0000-0001-7460-733X
LaRon E NelsonSchool of Nursing, University of Rochester, Rochester, NY, USA.
Craig W HendrixDepartment of Medicine (Clinical Pharmacology), John Hopkins School of Medicine, Baltimore, MD, USA.
Estelle Piwowar-ManningDepartment of Pathology, John Hopkins School of Medicine, Baltimore, MD, USA.
Steven ShoptawDepartment of Family Medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Phaedrea WatkinsScience Facilitation Department, FHI 360, Durham, NC, USA.
C Chauncey WatsonGilead Sciences, Foster City, CA, USA.
Leo WiltonDepartment of Human Development, State University of New York at BinghamtonBinghamton, NY, USA.
Fred Hutch Cancer Center · USFamily Health International 360 · USJohns Hopkins University · USMilken Institute · USBeth Israel Deaconess Medical Center · USBinghamton University · USGilead Sciences (United States) · USJohn Wesley Community Health Institute · USNew York Institute of Technology · USSt. Michael's Hospital · CAUniversity at Albany, State University of New York · USUniversity of California, Los Angeles · USUniversity of North Carolina at Chapel Hill · US

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Nina Thawata Harawa · 1997 to 2026
$53.5M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9M
SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Italo Mocchetti · 2015 to 2026
$29.6M
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)U01AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ERON, JOSEPH J · 2007 to 2011
$21.8M
UCLA AIDS Prevention and Treatment Clinical Trials UnitU01AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CURRIER, JUDITH S. · 2007 to 2011
$13.9M
Training Program for Scientists Conducting Research to Reduce HIV Health DisparitR25MH067127 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emily A Arnold, Torsten Brian Neilands · 2003 to 2026
$5.4M
NCATS NIH HHS UL1 TR001111NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI117970NIAID NIH HHS R21 AI069053NIAID NIH HHS U01 AI069423NIAID NIH HHS U01 AI069424NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069424NICHD NIH HHS R25 HD045810NIMH NIH HHS P30 MH058107NIMH NIH HHS R25 MH067127
6 · The paper itself

Abstract

introductionRandomized clinical trials have demonstrated the efficacy of antiretroviral pre-exposure prophylaxis (PrEP) in preventing HIV acquisition among men who have sex with men (MSM). However, limited research has examined initiation and adherence to PrEP among Black MSM (BMSM) in the United States (US) who are disproportionately represented among newly HIV infected and late to care individuals. This research reports on the HIV Prevention Trials Network 073 (HPTN 073) study aimed to examine PrEP initiation, utilization and adherence among Black MSM utilizing the theoretically principled, culturally informed and client-centered care coordination (C4) model.

methodsThe HPTN 073 study enrolled and followed 226 HIV-uninfected Black MSM in three US cities (Los Angeles, CA; Washington DC; and Chapel Hill, NC) from February 2013 through September 2015. Study participants were offered once daily oral emtricitabine/tenofovir (FTC/TDF) PrEP combined with C4 and followed up for 52 weeks. Participants received HIV testing, risk reduction education and clinical monitoring.

resultsOf the 226 men enrolled, 178 participants initiated PrEP (79%), and of these 64% demonstrated PrEP utilization at week 26 (mid-point of the study) based on pharmacokinetic testing. Condomless anal sex with an HIV-infected or unknown status casual male partner was statistically significantly associated with a greater likelihood of PrEP initiation (adjusted odds ratio (OR) 4.4, 95% confidence interval (CI) 1.7, 11.7). Greater age (≥25 vs. <25, OR 2.95, 95% CI 1.37 -6.37), perception of having enough money (OR 3.6, 95% CI 1.7 to 7.7) and knowledge of male partner taking PrEP before sex (OR 2.22, 95% CI 1.03 to 4.79) were statistically significantly associated with increased likelihood of PrEP adherence at week 26. Annualized HIV incidence was 2.9 (95% CI 1.2 to 7.9) among those who initiated PrEP, compared to 7.7 (95% CI 2.5 to 24.1) among those who did not initiate PrEP (p = 0.18).

conclusionsResults suggest a high level of PrEP initiation among at-risk Black MSM, a group historically characterized as hard to reach. The data support the importance of addressing contextual factors that affect PrEP initiation and adherence, and of additional research on the ultimate benefit of PrEP in HIV prevention among Black MSM.

Indexed as

Medication AdherenceAdolescentAdultAnti-HIV AgentsBlack or African AmericanCitiesEmtricitabineFemaleHealth SurveysHIV InfectionsHomosexuality, MaleHumansMaleMiddle AgedPre-Exposure ProphylaxisSexual PartnersAnti-HIV AgentsEmtricitabineTenofovirclient-centered care coordination (C4)HIV disparitiesHIV preventionMultiLevel interventionsPrEP adherencePrEP initiation

Identifiers

PMID30768776
PMCPMC6376611
OpenAlexW2914123147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.